SCHEMBL15422630

SCHEMBL15422630

O=C1C=CCCN1C(=O)C=CC(=O)N1CCC=CC1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.57
▸ TP53 P04637 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ MAPT P10636 2/20 0.57
▸ LMNA P02545 1/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ HIF1A Q16665 1/20 0.57
▸ PSMB11 A5LHX3 1/20 0.57
▸ PSMA7 O14818 1/20 0.57
▸ NPC1 O15118 1/20 0.57
▸ FOXO3 O43524 1/20 0.57
▸ MITF O75030 1/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ PSMB1 P20618 1/20 0.57
▸ PSMA1 P25786 1/20 0.57
▸ PSMA2 P25787 1/20 0.57
▸ PSMA3 P25788 1/20 0.57
▸ PSMA4 P25789 1/20 0.57
▸ PSMB8 P28062 1/20 0.57
▸ PSMB9 P28065 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15422627 1.00 ALDH1A1 (0.57) ALDH1A1TP53SMN1; SMN2MAPTLMNA
SCHEMBL21039243 0.87 ALDH1A1 (0.48) ALDH1A1TP53SMN1; SMN2MAPTLMNA
SCHEMBL15432080 0.86 ALDH1A1 (0.64) ALDH1A1TP53SMN1; SMN2MAPTLMNA
SCHEMBL21001951 0.85 ALDH1A1 (0.52) ALDH1A1TP53SMN1; SMN2MAPTLMNA
SCHEMBL21001950 0.85 ALDH1A1 (0.52) ALDH1A1TP53SMN1; SMN2MAPTLMNA
SCHEMBL22713020 0.85 ALDH1A1 (0.49) ALDH1A1TP53SMN1; SMN2MAPTLMNA
SCHEMBL21039170 0.85 ALDH1A1 (0.49) ALDH1A1TP53SMN1; SMN2MAPTLMNA
SCHEMBL15422036 0.85 ALDH1A1 (0.48) ALDH1A1TP53SMN1; SMN2MAPTLMNA
SCHEMBL21039167 0.83 ALDH1A1 (0.45) ALDH1A1TP53SMN1; SMN2MAPTLMNA
SCHEMBL15422540 0.82 SMN1; SMN2 (0.60) ALDH1A1TP53SMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108923-B2 Compounds, compositions, and methods for cancer therapy HOWARD HUGHES MEDICAL INSTITUTE (US) 2015-08-18 — — US disclosed
US-20140024639-A1 Compounds, Compositions, and Methods for Cancer Therapy NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-01-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024639-A1 Compounds, Compositions, and Methods for Cancer Therapy MCL1, TP53, VHL ALDH1A1 710/4885TP53 2/4885SMN1; SMN2 3402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback